New drug duo aims to shrink tumors before melanoma surgery
NCT ID NCT04207086
Summary
This study is testing whether giving two drugs—pembrolizumab and lenvatinib—for six weeks before surgery can better control stage III melanoma. The goal is to shrink the tumor and boost the body's immune response to improve long-term results after the operation. It involves 21 adults with resectable melanoma and will also look for clues in the blood and tissue about how the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Melanoma Institute Australia
North Sydney, New South Wales, 2060, Australia
Conditions
Explore the condition pages connected to this study.